Calorie restriction, a reduction in calorie intake without malnutrition, has been found to slow down the ageing process in several animal models from worms to mammals, and developing drugs that can reproduce this effect, without the side effects, could have widespread human applications.
Using complex genetic data analysis and testing, scientists at University of Liverpool in UK have shown for the first time that allantoin, which is found in botanical extracts of the comfrey plant and is an ingredient of many anti-ageing creams, can mimic the effect of calorie restriction and increase lifespan in worms by more than 20 per cent.
To identify potential calorie restriction mimetic compounds, the team used existing molecular signatures from human cells treated with a variety of small-molecule drugs.
Using pattern-matching algorithms to make connections between drug compounds and calorie restriction effects, eleven potential compounds were identified. Five of these were then tested in nematode worms.
The researchers found that worms treated with allantoin, rapamycin, trichostatin A and LY-294002 not only lived longer, but also stayed healthier longer.
Further molecular analysis of allantoin suggests it acts by a different mechanism from rapamycin, a well-known longevity drug.
"Testing anti-ageing interventions in humans is not practical, so developing computational methods to predict longevity drugs is of great use," said Shaun Calvert, PhD student at University of Liverpool.
"We have shown so far that our compounds work in worms, but studies in mammalian models are now necessary," Calvert said.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
